Argos Therapeutics, Inc. (NASDAQ:ARGS) was the recipient of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 5,592,879 shares, an increase of 106.7% from the October 13th total of 2,706,234 shares. Currently, 18.4% of the shares of the company are sold short. Based on an average trading volume of 1,859,733 shares, the short-interest ratio is presently 3.0 days.

A hedge fund recently bought a new stake in Argos Therapeutics stock. Wasatch Advisors Inc. bought a new position in shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned 1.21% of Argos Therapeutics as of its most recent SEC filing. 27.92% of the stock is owned by institutional investors.

Separately, Zacks Investment Research lowered Argos Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 14th. One research analyst has rated the stock with a sell rating and three have issued a hold rating to the company. Argos Therapeutics has a consensus rating of “Hold” and a consensus target price of $4.13.

Shares of Argos Therapeutics (ARGS) opened at $0.17 on Friday. Argos Therapeutics has a 1-year low of $0.13 and a 1-year high of $5.68. The company has a quick ratio of 1.51, a current ratio of 1.51 and a debt-to-equity ratio of -1.20.

Argos Therapeutics (NASDAQ:ARGS) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.01. The firm had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.10 million. Argos Therapeutics had a negative return on equity of 1,532.49% and a negative net margin of 12,391.15%.

COPYRIGHT VIOLATION NOTICE: This report was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.